Clinical trial · Observational
Comprehensive Frailty Assessment
NCT02033928CI-TRIAL-00031838completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health. With surveys, questionnaires and blood tests, we hope to create a tool that will give a good picture of patients' ability to tolerate treatment. In the future, we hope to devise the best treatment for a patient based on their "fitness".
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Neoplasms | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Myeloma, Multiple | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Paraproteinemias | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Arm I: Transplant patients
- label
- Arm II: Plasma cell dyscrasia patients
Primary outcomes (1)
- measure
- Change in Comprehensive Frailty Assessment
- timeFrame
- up to 14 months
- description
- Responses to the Comprehensive Frailty Assessment will be assessed before and after treatment and changes will be evaluated. In transplant patients, this will be measured one year post transplant and in the non-transplant arm, this will be assessed after the second cycle of treatment.
Secondary outcomes (1)
- measure
- Time to progression
- timeFrame
- date of enrollment to date of documented clinical progression up to two years post-enrollment
- description
- We will assess time to progression for multiple myeloma patients and the relationships of those outcomes to patients' functional, cognitive and psychosocial health.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with a plasma cell dyscrasia AND/OR any patient receiving a stem cell transplant for a hematologic malignancy at The Ohio State University * at least 18 years of age Exclusion Criteria: \- Any medical or psychiatric condition that would make it difficult for the patient to comply with study procedures.
References
Publications (0)
Data not yet available
No reference posted for this study.